Ocuphire Pharma (OCUP) announced the U.S. commercial launch of RYZUMVI by its partner Viatris (VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%. Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP:
- Ocuphire Pharma Engages Investors with Presentation Update
- Ocuphire Pharma price target lowered to $20 from $24 at Alliance Global
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
- Ocuphire Pharma expects cash to fund operations into mid-2025
- Ocuphire Pharma reports Q4 EPS (21c), consensus (5c)